Joint Initiative for Metrology in Biology, National Institute of Standards and Technology, 443 Via Ortega, Stanford, CA, 94305, USA.
Statistical Engineering Division, National Institute of Standards and Technology, Gaithersburg, MD, 20899, USA.
BMC Biotechnol. 2018 Mar 20;18(1):17. doi: 10.1186/s12896-018-0423-4.
We demonstrate the feasibility of creating a pair of reference samples to be used as surrogates for clinical samples measured in either a research or clinical laboratory setting. The reference sample paradigm presented and evaluated here is designed to assess the capability of a measurement process to detect true differences between two biological samples. Cell-based reference samples can be created with a biomarker signature pattern designed in silico. Clinical laboratories working in regulated applications are required to participate in proficiency testing programs; research laboratories doing discovery typically do not. These reference samples can be used in proficiency tests or as process controls that allow a laboratory to evaluate and optimize its measurement systems, monitor performance over time (process drift), assess changes in protocols, reagents, and/or personnel, maintain standard operating procedures, and most importantly, provide evidence for quality results.
The biomarkers of interest in this study are microRNAs (miRNAs), small non-coding RNAs involved in the regulation of gene expression. Multiple lung cancer associated cell lines were determined by reverse transcription (RT)-PCR to have sufficiently different miRNA profiles to serve as components in mixture designs as reference samples. In silico models based on the component profiles were used to predict miRNA abundance ratios between two different cell line mixtures, providing target values for profiles obtained from in vitro mixtures. Two reference sample types were tested: total RNA mixed after extraction from cell lines, and intact cells mixed prior to RNA extraction. MicroRNA profiling of a pair of samples composed of extracted RNA derived from these cell lines successfully replicated the target values. Mixtures of intact cells from these lines also approximated the target values, demonstrating potential utility as mimics for clinical specimens. Both designs demonstrated their utility as reference samples for inter- or intra-laboratory testing.
Cell-based reference samples can be created for performance assessment of a measurement process from biomolecule extraction through quantitation. Although this study focused on miRNA profiling with RT-PCR using cell lines associated with lung cancer, the paradigm demonstrated here should be extendable to genome-scale platforms and other biomolecular endpoints.
我们展示了创建一对参考样本的可行性,这些样本可作为在研究或临床实验室环境中测量的临床样本的替代品。这里提出和评估的参考样本范例旨在评估测量过程检测两个生物样本之间真实差异的能力。基于生物标志物特征设计的基于细胞的参考样本可以通过计算机设计来创建。在受监管应用中工作的临床实验室必须参与能力验证计划;从事发现工作的研究实验室通常不参与。这些参考样本可用于能力验证或作为过程控制,使实验室能够评估和优化其测量系统,随着时间的推移监测性能(过程漂移),评估方案、试剂和/或人员的变化,维护标准操作程序,最重要的是,提供质量结果的证据。
本研究中感兴趣的生物标志物是 microRNAs(miRNAs),即参与基因表达调控的小型非编码 RNA。通过逆转录(RT)-PCR 确定多种肺癌相关细胞系具有足够不同的 miRNA 谱,可作为混合物设计中的成分作为参考样本。基于成分谱的计算机模型用于预测两个不同细胞系混合物之间的 miRNA 丰度比,为从体外混合物中获得的谱提供目标值。测试了两种参考样本类型:从细胞系提取后混合的总 RNA,以及在提取 RNA 之前混合的完整细胞。从这些细胞系提取的 RNA 衍生的一对样品的 miRNA 分析成功复制了目标值。这些细胞系的完整细胞混合物也接近目标值,证明了作为临床标本模拟物的潜在用途。两种设计都证明了它们作为实验室间或实验室内部测试的参考样本的实用性。
可以从生物分子提取到定量为测量过程创建基于细胞的参考样本,以评估性能。虽然本研究重点是使用与肺癌相关的细胞系进行 RT-PCR 的 miRNA 分析,但这里展示的范例应该可以扩展到基因组规模的平台和其他生物分子终点。